ArticleDiscover oncology2026
The role of the miR-200a-5p/NFIA axis in the progression and clinical prognosis of non-small cell lung cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Pan-Cancer Analysis of microRNA Tissue Specificity and Its Association with Dysregulation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-small cell lung cancer (NSCLC) is characterized by a remarkably high mortality rate in clinical settings. This study aims to explore the mechanism of the miR-200a-5p/NFIA (nuclear factor I/A) axis in NSCLC and evaluate its potential as a clinical prognostic biomarker.
methodsThe study included 145 patients with NSCLC. The expression levels of miR-200a-5p and NFIA were quantified by quantitative reverse transcription polymerase chain reaction in tissues and cells. The prognostic value of miR-200a-5p was employed by Kaplan-Meier curves and Cox regression models. Cell proliferation, migration, and invasion were assessed using the cell counting kit-8 and Transwell assays. The potential target of miR-200a-5p were predicted by bioinformatics analysis. The interaction between miR-200a-5p and NFIA was validated by dual-luciferase assay.
resultsmiR-200a-5p was upregulated in NSCLC tissues and cells, while NFIA was downregulated. High expression of miR-200a-5p was associated with a poor prognosis in NSCLC patients. Overexpression of miR-200a-5p promoted cell proliferation, migration, and invasion. NFIA was a target gene of miR-200a-5p. Overexpression of NFIA partially reversed the promotion effect of miR-200a-5p on cell proliferation, migration, and invasion.
conclusionResearch findings indicate that miR-200a-5p is overexpressed in NSCLC, and the high expression of miR-200a-5p is an independent adverse prognostic factor for NSCLC patients. miR-200a-5p promotes cell proliferation, migration and invasion by targeting and inhibiting NFIA. Although these findings require further validation in multicenter cohorts and in vivo models, miR-200a-5p shows potential as an independent prognostic biomarker and a therapeutic target in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.